Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.
Cell
; 183(6): 1496-1507.e16, 2020 12 10.
Article
em En
| MEDLINE
| ID: mdl-33171099
ABSTRACT
Antibodies are key immune effectors that confer protection against pathogenic threats. The nature and longevity of the antibody response to SARS-CoV-2 infection are not well defined. We charted longitudinal antibody responses to SARS-CoV-2 in 92 subjects after symptomatic COVID-19. Antibody responses to SARS-CoV-2 are unimodally distributed over a broad range, with symptom severity correlating directly with virus-specific antibody magnitude. Seventy-six subjects followed longitudinally to â¼100 days demonstrated marked heterogeneity in antibody duration dynamics. Virus-specific IgG decayed substantially in most individuals, whereas a distinct subset had stable or increasing antibody levels in the same time frame despite similar initial antibody magnitudes. These individuals with increasing responses recovered rapidly from symptomatic COVID-19 disease, harbored increased somatic mutations in virus-specific memory B cell antibody genes, and had persistent higher frequencies of previously activated CD4+ T cells. These findings illuminate an efficient immune phenotype that connects symptom clearance speed to differential antibody durability dynamics.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Imunoglobulina G
/
Ativação Linfocitária
/
Linfócitos T CD4-Positivos
/
COVID-19
/
Anticorpos Antivirais
/
Formação de Anticorpos
/
Mutação
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article